

# **EXHIBIT 1**

# Inhibition of respiratory viruses by nasally administered siRNA

Vira Bitko, Alla Musiyenko, Olena Shulyayeva & Sailen Barik

Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that individual as well as joint infection by RSV and PIV can be specifically prevented and inhibited by short interfering RNAs (siRNAs), instilled intranasally in the mouse, with or without transfection reagents. The degree of protection matched the antiviral activity of the siRNA in cell culture, allowing an avenue for quick screening of an efficacious siRNA. When targeting both viruses in a joint infection, excess of one siRNA moderated the inhibitory effect of the other, suggesting competition for the RNAi machinery. Our results suggest that, if properly designed, low dosages of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against respiratory viral diseases in humans.

Viral infection of the respiratory tract is the most common cause of infantile hospitalization in the developed world with an estimated 91,000 annual admissions in the US at a cost of \$300 million<sup>1</sup>. RSV and PIV are two major agents of respiratory illness; together, they infect the upper and lower respiratory tracts, leading to croup, pneumonia and bronchiolitis<sup>1,2</sup>. RSV alone infects essentially all children within the first two years of life and is also a significant cause of morbidity and mortality in the elderly. Infants experiencing RSV bronchiolitis are more likely to develop wheezing and asthma later in life. Research towards effective treatment and a vaccine against RSV has been ongoing for nearly four decades with few successes<sup>1,3</sup>. Currently, no vaccine is clinically approved for either RSV or PIV. Strains of both viruses also exist for nonhuman animals, causing loss to agriculture and the dairy and meat industries<sup>2</sup>.

RSV and PIV both contain nonsegmented negative-strand RNA genomes and belong to the *Paramyxoviridae* family. A number of features of these viruses have contributed to the difficulties of prevention and therapy. The RNA genomes mutate rapidly because of the lack of a proofreading mechanism during replication<sup>4</sup>. Promising inhibitors of the RSV fusion protein were abandoned partly because of resistant mutations that mapped to the F gene<sup>5,6</sup>. Both viruses associate with cellular proteins, adding to the difficulty of obtaining cell-free viral material for vaccination<sup>7</sup>. The immunology of both viruses, and especially that of RSV, is complex<sup>10,11</sup>; use of denatured RSV proteins as vaccines leads to 'immunopotential' or vaccine-enhanced disease<sup>11,12</sup>, and this phenomenon has not been ruled out for PIV. The overall problem is underscored by the recent closure of a number of anti-RSV biopharmaceutical programs<sup>3</sup>.

Faced with these barriers to the traditional anti-viral strategies, we tested RNAi<sup>13</sup> against these viruses. Using RSV as a model, we had previously shown that double-stranded siRNAs could function as efficient

antiviral treatments in cell culture<sup>14</sup>; siRNA targeting the P protein, an essential subunit of the viral RNA-dependent RNA polymerase, strongly inhibited all RSV gene expression and RSV growth in culture<sup>14</sup>. In PIV infection, knockdown of hemagglutinin-neuraminidase and fusion proteins led to the abrogation of virus-mediated cell fusion<sup>15</sup>. Here, we applied siRNA to RSV and PIV infections in mice, and show that single as well as concurrent infections can be prevented and treated by specific siRNA applied exclusively intranasally. Our findings suggest that inhaled siRNA could be a promising strategy for anti-RSV and anti-PIV therapy in humans.


## RESULTS

### Designing antiviral siRNAs against RSV and PIV phosphoprotein mRNA

We had shown earlier that an siRNA satisfying the original AA(N)<sub>19</sub>TT sequence rule<sup>16</sup> efficiently knocked down RSV Long strain P expression in cell culture (*ex vivo*)<sup>14</sup>. Various studies have since led to semi-empirical rules for designing efficient siRNAs<sup>17–19</sup>, the most important being the 'asymmetry rule' whereby the 5' end of the guide strand (antisense strand) of the siRNA should be richer in AU (i.e., thermodynamically less stable) than the 3' end. This leads to preferential unwinding of the siRNA at this end and incorporation of the antisense strand into the siRNA-induced silencing complex (RISC)<sup>18,19</sup>. Web-based algorithms are now available that incorporate these rules. We used one such service offered by the Whitehead Institute to design additional siRNA against RSV P and new siRNAs against PIV P mRNA. The siRNAs were synthesized chemically<sup>14</sup> and their IC50 (concentration of siRNA producing 50% reduction of target) *ex vivo* was determined (Fig. 1a and Table 1). Two siRNAs against RSV (#1, #2) and one against PIV (#4) showed appreciable inhibition and were selected for further study. Notably, the

Department of Biochemistry and Molecular Biology (MSB 2370), University of South Alabama, College of Medicine, 307 University Boulevard, Mobile, Alabama 36688-0002, USA. Correspondence should be addressed to S.B. (sbarik@jaguar1.usouthal.edu).

Published online 26 December 2004; doi:10.1038/nm1164



**Figure 1** Titration of antiviral siRNAs *ex vivo*. (a) Immunoblot analysis of total proteins of RSV-infected A549 cells (*ex vivo*) with profilin as the internal control<sup>8</sup>. Numbers in the box represent levels of target P mRNA following siRNA treatment, expressed as percentage of untreated levels. In the following three panels, virus was administered 4 h after siRNA. (b) Pulmonary infectious virus in RSV-infected mice ( $n = 8$  for each data point). (c) Pulmonary infectious virus in PIV-infected mice ( $n = 8$  for each data point). (d) As in b except that naked siRNA was administered without any transfection reagent. Asterisks indicate significant inhibition ( $P < 0.05$ ). siRNAs are described in Table 1.

respiratory distress), suggesting a favorable pharmacology for drug development.

Specific antiviral effects of intranasal siRNA prevent lung infection. Although the results presented above documented inhibition of viral replication, they did not directly prove abrogation of infection. Therefore, we probed sections of both lungs 5 d after infection with virus-specific antibodies. Intranasal pretreatment with 5 nmol (70  $\mu$ g) of anti-RSV siRNA#1 complexed with TransIT-TKO abolished RSV infection (Fig. 2a). Similar reduction of PIV infection was also seen with anti-PIV siRNA#4. siRNA administered without transfection reagent also showed substantial reduction of infection, as shown for RSV. We estimate that the reagent-free siRNA was 70–80% as effective as siRNA complexed with TransIT-TKO. Thus pure naked siRNA, free of other chemicals, may offer substantial protection against respiratory pathogens. This is particularly important as transfection reagents themselves may have adverse effects. We note here that polyethyleneimine has been successfully used as a carrier for intravenous as well as intratracheal delivery of siRNA and DNA against influenza virus<sup>24</sup>. In our experience, however, direct intranasal administration of polyethyleneimine, with or without siRNA, often resulted in overt sickness and/or death of the mouse.

Intranasal siRNAs localize to the lung and do not activate IFN. To provide further evidence that the viral inhibition was a direct and specific effect of intranasal siRNA, two further experiments were performed. First, we detected the antisense strand of the siRNA in the lung tissue (Fig. 2b) by northern analyses. Second, the possibility that the antiviral effect of siRNAs was the result of activation of interferons (IFNs)

original siRNA to RSV (#1)<sup>14</sup> had the lowest IC<sub>50</sub> of ~18 nM but was the most unfavorable by the asymmetry criteria and was not suggested by several design engines including those of Whitehead and Dharmason, indicating the need for experimental verification of siRNAs. Levels of target mRNA correlated with levels of protein after siRNA treatment (shown for siRNA#1 in Fig. 1a).

**Intranasal siRNAs inhibit RSV and PIV replication in mouse lung**  
To determine whether the siRNAs that were active *ex vivo* would be effective *in vivo*, we performed experiments in the BALB/c mouse, a well-established animal model for RSV infection<sup>20–22</sup>. We administered siRNAs complexed with TransIT-TKO reagent intranasally and 4 h later challenged each animal with 10<sup>7</sup> plaque-forming units (p.f.u.) of RSV or PIV, also intranasally. Previous experiments<sup>21,22</sup> and our results showed that maximal RSV growth in mouse lung occurs around 5–6 d after infection. In our routine experiments, therefore, we selected this time point for evaluation of siRNA efficacy and found that siRNAs that were effective *ex vivo* (Fig. 1a) were indeed highly effective *in vivo* (Fig. 1b,c). At a dose of 5 nmol intranasal siRNA (averaging ~70  $\mu$ g for double-stranded siRNAs) per mouse, siRNA#1 and siRNA#4, respectively, reduced pulmonary RSV and PIV titer by about 99.98% and 99% (Fig. 1b,c). Notably, siRNAs alone, free of transfection reagents, also significantly inhibited ( $P < 0.05$ ) pulmonary viral titers (Fig. 1d). It is to be noted that PIV does not infect the mouse as readily as RSV<sup>23</sup>, which is the reason for the relatively lower PIV replication in the mouse lung (Fig. 1c).

The virus inhibition was highly specific (Fig. 1); even the most potent anti-RSV siRNA (#1) did not inhibit PIV, and vice versa. Furthermore, anti-luciferase siRNA<sup>16</sup> did not inhibit either virus (Fig. 1b–d). Finally, intranasal siRNAs with or without the TransIT-TKO reagent caused no obvious discomfort in uninfected mice (as judged by normal coat, activity, appetite and weight gain, and lack of

**Table 1** siRNA sequences

Name	Target	siRNA sequence	IC <sub>50</sub> (nM)
siRNA#1	RSV-P	5'-CGAUAUUAUACUGCAAGdTt-3' 3'-dTtGCUUAUUAUACUGUUCU-5'	18
siRNA#2	RSV-P	5'-CCCUCACCAACGUGUAUdTt-3' 3'-dTtGGGAUGUGUUCACUUA-5'	80
siRNA#3	RSV-P	5'-GAGGCCAUGAUGUUAAdtTt-3' 3'-dTtCUACGUAUACUACCAUU-5'	>300
siRNA#4	HPIV3-P	5'-CGAGUUGUAGUGUAGCAAdtTt-3' 3'-dTtGCUACACUACACUAGUU-5'	15
siRNA#5	HPIV3-P	5'-GAUAGACUUCUAGCAGAdtTt-3' 3'-dTtCUACUAGAGGAGUUCUUCU-5'	>300
Luc-siRNA	Luciferase	5'-CGUACGCGGAAUACUUGAdtTt-3' 3'-dTtGAGGCGGCUUAGAGAGCU-5'	–
Negative	–	5'-UUUCUCCGACGUGUCACGdTt-3' 3'-dTtAAGAGGCGUACGAGUGCA-5'	–

Note that the siRNA sequences were based on actual sequencing of the viral strains in our laboratory; thus, siRNA#2 differs by one nucleotide from the GenBank sequence (the underlined C is U in M22644). Negative control siRNA sequence was from Qiagen.

**Figure 2** Knockdown of viral antigens in siRNA-treated mouse lung without IFN activation. (a) Virus was administered 4 h after siRNA, and viral antigens were detected by indirect immunohistology of lungs at 4 d after infection (green, RSV; red, PIV). Bar, 400  $\mu$ m. (b) Antisense strand of siRNA#1 was detected by northern analysis of varying amounts of total lung RNA 2 d after siRNA administration using labeled RSV P DNA as probe. A probe against RSV NS1 did not react, showing specificity of detection. (c) Intranasal siRNA (10 nmol or 140  $\mu$ g per mouse) did not activate pulmonary IFN- $\alpha$  or IFN- $\gamma$  above the threshold of detection ( $<10$  pg/ml), whereas in control lungs, RSV infection activated type II and low levels of type I. Lanes: 1, siRNA#1; 2, siRNA#4; 3, luc siRNA; 4, no siRNA but RSV-infected; error bars indicate s.e.m. Lungs were obtained 2 d after siRNA administration and 4 d after infection ( $n = 4$  for each graph). (d) siRNA-mediated inhibition of dual infection by RSV and PIV determined by indirect immunohistology (green, RSV; red, PIV). Virus was administered 4 h after siRNA, and lung tissues were examined at 4 d after infection. Bar, 400  $\mu$ m.


was ruled out. Paramyxoviruses in general encode diverse mechanisms to counteract IFNs; RSV, in particular, is largely resistant to type I IFNs (IFN- $\alpha$  and IFN- $\beta$ ) although sensitive to type II IFN (IFN- $\gamma$ )<sup>25,26</sup>. Our early studies showed that the siRNAs were active against RSV and PIV in Vero cells that contain deletions of the genes that encode type I IFN (data not shown). Direct measurement of IFN- $\alpha$  and IFN- $\gamma$  in mouse lung following treatment with various siRNAs showed no activation of either type of IFN (Fig. 2c).

siRNAs competitively inhibit RSV and PIV in mixed infection In some studies joint infection by RSV and PIV has been diagnosed<sup>1,27</sup>. In fact, chimeric viruses and recombinant vaccines incorporating both RSV and PIV antigens were constructed on the premise that they would offer simultaneous protection against both viruses<sup>28,29</sup>. The specific antiviral effect of siRNA#1 and siRNA#4 against RSV and PIV, respectively, prompted us to test them together (5 nmol or 70  $\mu$ g of each) in mixed infection by both viruses. As there is no easy way to determine the number of plaque-forming units (p.f.u.) of each virus in a mixture of the two, we resorted to immunofluorescence microscopy of the lung tissue sections using antibodies specific for RSV and PIV. Indeed, pretreatment with siRNA#1 and siRNA#4 specifically prevented infection by RSV and PIV, respectively (Fig. 2d). A combination of the two siRNAs (5 nmol or 70  $\mu$ g of each) inhibited both viruses (Fig. 2d). As before, the same siRNA mix without any transfection reagent was also highly effective (data not shown).

Notably, when excessively high amounts of one siRNA were used, the inhibitory activity of the other was reduced (Fig. 3). Quantitative real-time RT-PCR showed that the IC<sub>50</sub> of siRNA#4 (against PIV P) ex vivo increased through 15, 35 and 100 nM as the concentration of siRNA#1 (against RSV P) was raised from 0 to 20 to 200 nM (Fig. 3a). Measurement of PIV P protein in immunoblot validated these results (Fig. 3b). In vivo, immunoblot quantification of viral N proteins also led to a similar result: whereas 5 nmol (70  $\mu$ g) of each siRNA effectively inhibited both viruses, 50 nmol of one siRNA reduced the effect of 5 nmol of the other in a mutual manner (Fig. 3c).

### Intranasal siRNAs prevent pulmonary pathology


Because the siRNAs prevented infection, we next asked whether they inhibited the pathological features as well. Upon visual inspection, the siRNA-treated RSV-exposed mice behaved like uninfected mice with normal activity, shiny coat and general well-being. We then measured the respiratory rate, leukotriene induction and pulmonary inflammation. Respiratory rate of BALB/c mice is known to increase in response to RSV infection<sup>31,32</sup>. Leukotrienes, products of the lipoxygenase pathway,



bind to the leukotriene receptors present in bronchial smooth muscle and are elevated in the respiratory secretions of asthmatic patients and RSV-infected infants and mice<sup>31,32</sup>. These compounds provoke airway mucus secretion, bronchoconstriction and infiltration by inflammatory cells, which are hallmarks of severe RSV disease<sup>10-12,22,31,32</sup>. When we administered siRNA#1 at the same time as (or before) RSV, considerable reductions in all these parameters were observed (Fig. 4). The values were essentially comparable to those in sham-infected mice at least up to 14 d after infection, showing that the siRNA prevented illness and did not simply postpone it. In fact, siRNA-treated mice showed no visible signs of respiratory distress up to 6 weeks of observation. Negative control RNA or luc-siRNA (Table 1) offered no relief in all experiments (data not shown).

### Intranasal siRNAs are effective antivirals after infection

Having shown that siRNAs can prevent respiratory viral disease if administered before infection, we asked whether they may have a curative effect once infection has established, as this is an important goal in pediatric medicine. The RSV-infected mice maintained their body weight for about 4 d after infection, followed by a gradual loss that continued at least up to 9 d, confirming previous observations<sup>22</sup> (Fig. 5a). In contrast, mice treated with siRNA before (data not shown) or at the same



**Figure 3** Competitive viral inhibition at high siRNA concentration in dual infection by RSV and PIV. (a) Real-time PCR (ex vivo). (b) Immunoblot (ex vivo). (c) Pulmonary immunoblot with goat antiviral antibodies. The respective viral N protein band intensity was quantified and expressed as percentage of siRNA-untreated lung samples. Virus was administered 4 h after siRNA, and lung tissues were at 5 d after infection. ( $n = 4$  for each data point). Black bar, RSV; gray bar, PIV. Standard errors are as shown.


time as RSV (day 0) continued to gain weight without interruption. Most mice receiving siRNA on day 1 were also difficult to distinguish from the sham-infected controls. Those receiving siRNA at subsequent days (day 2–4) showed gradually less and less protection, although we still observed substantial improvement of weight.

A similar picture emerged when we determined pulmonary RSV titer (Fig. 5b). In the infected mice, the titer rose until day 4–5, and then slowly dropped to undetectable levels by day 16. siRNA treatment before or concomitant with RSV infection reduced the titer by ~99.98% at all days tested. Administration of siRNA at later times in infection was progressively less effective, but the viral titer was generally lower than the untreated controls on any day tested. Control siRNAs (Table 1) had no effect (data not shown). Together, these results showed that the RSV siRNA had a curative effect when administered after infection and that the treated mice were always less sick and recovered more rapidly than their untreated cohorts.

## DISCUSSION

The principal finding of this paper is that appropriately designed siRNAs, applied intranasally, offer protection from respiratory infection, as well as providing considerable therapeutic value when administered after infection. We suggest that siRNAs, delivered by small particle aerosols in a simple hand-held inhaler, might prevent or cure pulmonary infections in humans. In pioneering recent work, siRNA offered protection

from hepatitis virus, and siRNA against the Fas antigen prevented liver damage resulting from fulminant hepatitis<sup>33,34</sup>. In these studies, a large bolus of siRNA was delivered under high pressure (hydrodynamically) through the tail vein of mice, which is impossible in humans. While our manuscript was in preparation, two reports appeared in which siRNAs inhibited influenza virus in a mouse model<sup>24,35</sup>. In one study<sup>24</sup>, synthetic siRNA and plasmid DNA expressing siRNA were administered through intravenous or intratracheal routes. In the other study<sup>35</sup>, siRNA was first administered by hydrodynamic intravenous delivery; 16–24 h later, the mice were infected with influenza virus and given a second dose of siRNA in a lipid carrier, both by the intranasal route. Quantification of pulmonary virus 2 d later showed considerable inhibition of the virus. Our studies offer the following improvement and simplification over the previous studies: (i) the delivery is solely intranasal and therefore, relatively noninvasive and painless, making it amenable to an inhaler or mist-based therapy; (ii) intranasal siRNA without any carrier is significantly effective, thus reducing the potential risk of carrier side effects; (iii) a single intranasal dose of ~5 nmol siRNA (70  $\mu$ g of double-stranded RNA) seems to provide benefit over the full duration of infection. siRNAs may show various degrees of nonspecific, off-target effects, especially at high concentrations<sup>36–39</sup>, and systemic side effects are a common concern in therapy. Low dosage of intranasal siRNA is more likely to be concentrated—if not exclusively localized—in the respiratory tissues, thus minimizing the side effects. Lack of IFN activation by intranasal



**Figure 4** Relief of lung pathology and reduction of an asthma marker in siRNA-treated mice. (a) Respiratory rate. (b) Pulmonary histopathology. (c) Leukotriene in bronchoalveolar lavage fluid (BALF).  $P < 0.002$  in all assays;  $n = 4$  for all data points; standard error bars are shown. Virus was administered at 4 h after siRNA (70  $\mu$ g). Mice treated with negative control siRNA were indistinguishable from siRNA-untreated (data not shown).

siRNA supports and extends previous findings that chemically synthesized siRNAs, devoid of 5' phosphates, do not activate the IFN pathway in cell culture<sup>40</sup>. A more comprehensive screening of the target sequence (e.g., RSV P) and use of newer chemistry may lead to siRNAs with even lower IC50s and better pharmacokinetics. Together, the correlation of antiviral activity with specific mRNA knockdown (Fig. 1), detection of the siRNA in the target tissue (lung) (Fig. 2b), lack of IFN activation (Fig. 2c), and the virus-specific effect of the siRNAs (Figs. 1–3) all provide evidence that the antiviral effect in the animal is specific, directed and RNAi-mediated. Finally, respiratory viruses show high selectivity in infecting the respiratory tissues. Thus, intranasal delivery ensures that the siRNA is targeted to the site of infection—an ideal condition for pharmacology.


The reason behind the observed inhibition of one siRNA by another must await further study and a better knowledge of the interaction between the two viruses. It is known that the RNAi machinery in a cell is saturable and thus, two siRNAs could compete for a fixed pool of this machinery<sup>15,41</sup>. Note that such competition (Fig. 3) was only appreciable at relatively high doses of the siRNAs (i.e., with tens or hundreds of nanomoles). In contrast, only a few nanomoles of our siRNAs offered nearly complete protection. Thus, the observed competition is not a matter of practical concern with siRNAs that have an IC50 in the low nanomolar range.

When used as a prophylactic, the siRNA not only prevented infection but also inhibited the disease as measured by clinical parameters (Fig. 4). When used as a treatment drug after infection, the siRNAs are not expected to correct the pathology that has already occurred. Even then, inhibition of further growth of the virus resulted in more rapid cure and recovery (Fig. 5). Thus, it seems that a large window of opportunity for treatment exists, although earlier treatments should produce better prognosis. The effectiveness of the naked siRNA remains to be explained. It is possible that the respiratory tissue, especially the lung, is naturally more receptive to the exchange of small molecules, or perhaps becomes so when infected.

Depending on the stringency of siRNA-target base pairing, siRNA treatment may cause selection of siRNA-resistant viruses, and this has been shown with HIV<sup>42</sup>. We have not faced this problem to date. Viruses recovered from the siRNA-treated mouse lung were grown in A549 cell culture and were equally susceptible to the siRNA as the original inoculum (data not shown). Moreover, sequencing of the siRNA region of the P gene in six such independent plaque-purified RSV isolates revealed the parental sequence (data not shown). Even if occasional resistance is encountered in the future, a second siRNA with a low IC50 and targeting a different region of the P mRNA or a different viral mRNA can be used in a multidrug regimen, thereby reducing the chances of viral resistance.

## METHODS

Virus, siRNA and other reagents. Human RSV Lung and PIV type 3 JS strains are abbreviated here as RSV and PIV, respectively. Both were grown on HEp-2 monolayers<sup>7,8</sup> and purified by sucrose gradient centrifugation<sup>43</sup>. The final preparations had titers<sup>7,8</sup> in the range of  $10^{6.5}$ – $10^8$  p.f.u./ml. We purchased siRNAs and TransIT-TKO reagent from Dharmacon and Mirus Bio Corp, respectively. Rabbit RSV-P antibody was used in immunohistological staining<sup>44</sup>. Goat HRV and HPIV3 antibodies were from Chemicon and Biospecific, respectively.



**Figure 5** Therapeutic effect of siRNA in RSV disease. Changes in (a) body weight and (b) pulmonary viral titer during RSV infection in mice. Standard error bars are shown;  $n = 6$  for each data point. The arrows indicate the day of siRNA (70  $\mu$ g) administration. The dashed line is the lower limit of detection of viral titer.

Virus infection and siRNA treatment. siRNA treatment of A549 monolayers have been described<sup>44,45</sup>. We purchased female BALB/c mice, 8–10 weeks old and weighing 16–20 g, from Charles River Laboratories. Anesthesia for administration of siRNA or virus was achieved with intraperitoneal injection of 0.2 ml nembutal (5 mg/ml). Mice were killed by cervical dislocation following anesthesia with 0.3 ml nembutal. We diluted the siRNA in the buffer provided by the manufacturer so that the desired amount was contained in 1  $\mu$ l; we mixed this with 5  $\mu$ l of TransIT-TKO reagent and 35  $\mu$ l of Opti-MEM (Gibco Life Technologies, Invitrogen) to produce a total volume of 41  $\mu$ l. When siRNA was used without carrier, the transfection reagent was substituted with Opti-MEM. We diluted virus in phosphate-buffered saline (PBS) such that 30  $\mu$ l contained  $10^7$  p.f.u. Sham infection was performed with the same volume of virus-free PBS. We equally divided siRNA mix and virus into two nostrils and applied with a micropipette (i.e., each nostril received 35  $\mu$ g siRNA in 20.5  $\mu$ l and  $0.5 \times 10^7$  virus in 15  $\mu$ l). For dual infection, we diluted virus stocks such that each mouse received a mixture of  $10^7$  p.f.u. of each virus and a mixture of 5 nmol (70  $\mu$ g) each of siRNA#1 and siRNA#4 in the same volumes as before. Animal experiments obeyed all prescribed guidelines and were approved by the Institutional Animal Care and Use Committee.

**Pulmonary viral assay and clinical measurements.** We weighed mice daily and checked them for disease symptoms. We determined respiratory rate by video recording<sup>31</sup>. Lungs were removed at various days after infection for the following analyses.

To determine viral titer, we homogenized the lungs in Dulbecco Modified Eagle Medium plus 2% fetal bovine serum (2 ml per 100 mg tissue). The extract was centrifuged at 2,000g for 10 min, and serial dilutions of the supernatant were assayed for plaque-forming units. For immunoblot of viral proteins<sup>7</sup>, we added 10  $\mu$ l of the homogenized sample to 10  $\mu$ l of 2  $\times$  SDS-PAGE sample buffer. The mixture was heated at 98  $^{\circ}$ C for 5 min, clarified by centrifugation and analyzed by immunoblot. IFN content<sup>44</sup> of lung homogenates in PBS were assayed by ELISA kits (R&D Systems) with detection limits of 10 pg/ml. We determined pulmonary histopathology in paraffin-embedded sections stained with hematoxylin and eosin<sup>42</sup>.

For immunohistology<sup>22</sup>, we embedded the lung tissue in 100% OCT compound and froze the tissue at  $-80^{\circ}$ C. Sections were cut onto slides, air-dried, fixed in acetone, washed with PBS permeabilized with 0.2% Triton X-100 in PBS and blocked for 20 min with 10% goat serum in PBS at room temperature. After further washes in PBS, we incubated the tissue for 2 h at room temperature with either anti-RSV-P (rabbit) or anti-PIV (goat) antibody diluted in PBS containing 1.5% goat serum. We washed the slides again and detected the two antibodies with FITC-conjugated anti-rabbit antibody and TRITC-conjugated anti-goat antibody, respectively<sup>44</sup>.

We collected bronchoalveolar lavage fluid by perfusing the bronchi and the lungs with  $5 \times 1.0$  ml normal saline (containing 10  $\mu$ g indomethacin per ml)<sup>39</sup>. Total recovery was 4.2–4.4 ml per mouse and cells were removed by centrifuga-

tion at 5,000g for 15 min at 4 °C. The concentration of cysteinyl leukotrienes conjugates in the bronchoalveolar lavage fluid was determined by ELISA kits (R&D Systems).

We performed real-time PCR on the iCycler IQ Quantitative PCR system from BioRad Laboratories using the iQ Sybr Green SuperMix. RNA was isolated from infected cells and first-strand cDNA made using the GeneAmp RNA PCR Core kit (Perkin-Elmer Applied Biosystems). Primers for PIV mRNA were: 5'-GGTCACTCAGACAGATGCAAC-3' and 5'-CTTGGAACATCTGCAGATTGTC-3'. We calculated gene expressions using the manufacturer's software with GAPD as the internal control. The antisense strand of siRNA in the lung was extracted and detected by northern hybridization<sup>45</sup>.

Statistical analysis. We analyzed changes by one-way ANOVA and then by Student's *t*-test with Bonferroni correction. Increases in leukotriene concentrations were determined by the Mann-Whitney test. We collected all numerical data from at least three separate experiments. Results were expressed as mean  $\pm$  s.e.m. (error bars in graphs). Differences were considered to be significant at  $P < 0.05$ .

URLs. Tuschl Laboratory <http://www.rockefeller.edu/labheads/tuschl/sirna.html>  
Whitehead Institute <http://jura.wi.mit.edu/sirnaext/>

Accession numbers. GenBank accession numbers for RSV-P, HPIV3-P and luciferase sequences are M22644, Z11575 and X65324, respectively.

#### ACKNOWLEDGMENTS

We thank A. Gard for use of the immunofluorescence microscope, S. Moyer (University of Florida) for a fresh HPIV3 inoculum, S. Pfeffer and T. Tuschl (Rockefeller University, NY) for advice on small RNA isolation, M. Ramaswamy (University of Iowa) for information on RSV-IFN relationship, R. Meyers (Alnylam Pharmaceuticals, Cambridge) for critical comments, and T. Barik for figure preparation. This research was supported in part by a grant from National Eye Institute (EY013826) and a NRSF Fellowship (A049682) from the National Institute of Allergy and Infectious Diseases (NIH). Preliminary results were presented in the Keystone Symposium on "siRNAs and miRNAs" April 14–19, 2004, Keystone, Colorado, USA.

#### COMPETING INTERESTS STATEMENT

The authors declare that they have no competing financial interests.

Received 12 July; accepted 27 October 2004

Published online at <http://www.nature.com/naturemedicine/>

- Openshaw, P.J.M. Potential therapeutic implications of new insights into respiratory syncytial virus infection. *Respir. Res.* 3 (Suppl 1), S15–S20 (2002).
- Easton, A.J., Omoschowski, J.B. & Rosenberg, H.F. Animal pneumoviruses: molecular genetics and pathogenesis. *Clin. Microbiol. Rev.* 17, 390–412 (2004).
- Magoni, K. & Barik, S. New drugs and treatment for respiratory syncytial virus. *Rev. Med. Virol.* 14, 149–168 (2004).
- Sullender, W.M. Respiratory syncytial virus genetic and antigenic diversity. *Clin. Microbiol. Rev.* 13, 1–15 (2000).
- Razinov, V., Huntley, C.C., Elestiadou, G. & Krishnamurthy, G. RSV entry inhibitors block P-protein mediated fusion with model membranes. *Antivir. Res.* 55, 189–200 (2002).
- Morton, C.J. et al. Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay. *Virology* 311, 275–288 (2003).
- Burke, E., Oupuy, L., Wall, C. & Barik, S. Role of cellular actin in the gene expression and morphogenesis of human respiratory syncytial virus. *Virology* 252, 137–148 (1998).
- Burke, E., Mahoney, N.M., Alm, S.C. & Barik, S. Profilin is required for optimal actin-dependent transcription of respiratory syncytial virus genome RNA. *J. Virol.* 74, 669–675 (2000).
- Gupta, S., Oe, P., Drazba, J.A. & Banerjee, A.K. Involvement of actin microfilaments in the replication of human parainfluenza virus type 3. *J. Virol.* 72, 2655–2662 (1998).
- Pavles, R.S., Jr., Hashimoto, K. & Graham, B.S. The complex relationship between respiratory syncytial virus and allergy in lung disease. *Vir. Immunol.* 16, 25–34 (2003).
- Haynes, L.M., Jones, L.P., Barsky, A., Anderson, L.J. & Tripp, R.A. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. *J. Virol.* 77, 9831–9844 (2003).
- Polack, F.P. et al. A role for immune complexes in enhanced respiratory syncytial virus disease. *J. Exp. Med.* 196, 859–865 (2002).
- Novina, C.D. & Sharp, P.A. The RNAi revolution. *Nature* 430, 161–164 (2004).

- Bitko, V. & Barik, S. Phenotypic silencing of cytoplasmic genes using sequence specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. *BMC Microbiol.* 1, 34 (2001).
- Barik, S. Control of nonsegmented negative-strand RNA virus replication by siRNA. *Virus Res.* 102, 27–35 (2004).
- Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411, 494–498 (2001).
- Reynolds, A. et al. Rational siRNA design for RNA interference. *Nat. Biotechnol.* 22, 326–330 (2004).
- Schwartz, D.S. et al. Asymmetry in the assembly of the RNAi enzyme complex. *Cell* 115, 199–208 (2003).
- Khvorov, A., Reynolds, A., & Jayasena, S.O. Functional siRNAs and miRNAs exhibit strand bias. *Cell* 115, 209–216 (2003). Erratum in: *Cell* 115, 505 (2003).
- Graham, B.S., Perkins, M.D., Wright, P.F. & Karzon, O.T. Primary respiratory syncytial virus infection in mice. *J. Med. Virol.* 28, 153–162 (1988).
- van Schaik, S.M., Enhom, G., Vargas, I. & Welliver, R.C. Respiratory syncytial virus affects pulmonary function in BALB/c mice. *J. Infect. Dis.* 177, 269–276 (1998).
- Haeblerle, H.A. et al. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology. *J. Virol.* 75, 878–890 (2001).
- Durban, A.P., Ekins, W.R. & Murphy, B.R. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types 1, -2, and -3 infection. *Vaccine* 18, 2462–2469 (2000).
- Ge, Q., Philip, L., Bai, A., Nguyen, T., Eiken, H.N. & Chen, J. Inhibition of influenza virus production in virus-infected mice by RNA interference. *Proc. Natl. Acad. Sci. USA* 101, 8676–8681 (2004).
- Schlender, J., Bossert, B., Buchholz, U. & Conzelmann, K.-K. Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. *J. Virol.* 74, 8234–8242 (2000).
- Ramaswamy, M., Shi, L., Montic, M.M., Hunninghake, G.W. & Look, D.C. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. *Am. J. Respir. Cell Mol. Biol.* 30, 893–900 (2004).
- Coras, M.T., Aguilar, J.C., Garcia, M.L., Casas, I. & Perez-Brena, P. Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested-PCR assays. *J. Med. Virol.* 72, 484–495 (2004).
- Haller, A.A., Mitiku, M. & MacPhail, M. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. *J. Gen. Virol.* 84, 2153–2162 (2003).
- Schmidt, A.C., McJuliffe, J.M., Murphy, B.R. & Collins, P.L. Recombinant bovine human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. *J. Virol.* 75, 4594–4603 (2001).
- Bernhard, W. et al. Phosphatidylcholine molecular species in lung surfactant: composition in relation to respiratory rate and lung development. *Am. J. Respir. Cell Mol. Biol.* 25, 725–731 (2001).
- Volotiz, B., Welliver, R.C., Oe, Castro, G., Krystofik, O.A. & Ogra, P.L. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. *Pediatr. Res.* 24, 504–507 (1988).
- Welliver, R.C., Znd, Hintz, K.H., Giori, M. & Welliver, R.C., Sr. Zileuton reduces respiratory illness and lung inflammation during respiratory syncytial virus infection in mice. *J. Infect. Dis.* 187, 1773–1779 (2003).
- McCaffrey, A.P. et al. Inhibition of hepatitis B virus in mice by RNA interference. *Nat. Biotechnol.* 21, 639–644 (2003).
- Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. *Nat. Med.* 9, 347–351 (2003).
- Tomkins, S.M., Lo, C.Y., Tumour, T.M. & Epstein, S.L. Protection against lethal influenza virus challenge by RNA interference in vivo. *Proc. Natl. Acad. Sci. USA* 101, 8682–8686 (2004).
- Jackson, A.L. et al. Expression profiling reveals off-target gene regulation by RNAi. *Nat. Biotechnol.* 21, 635–637 (2003).
- Slack, C.A., Hoko, M., de Vries, M.J., Silverman, R.H. & Williams, B.R. Activation of the interferon system by short-interfering RNAs. *Nat. Cell Biol.* 5, 834–839 (2003).
- Persengiev, S.P., Zhu, X. & Green, M.R. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). *RNA* 10, 12–18 (2004).
- Bridge, A., Peharand, S., Ducruet, A., Nicolau, A.L. & Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. *Nat. Genet.* 34, 263–264 (2003).
- Kim, D.H. et al. Interferon induction by siRNAs and ssRNAs synthesized by polymerase. *Nat. Biotechnol.* 22, 321–325 (2004).
- Hutvagner, G., Simard, M.J., Mello, C.C. & Zamore, P.O. Sequence-specific inhibition of small RNA function. *PLoS Biol.* 2, E98 (2004).
- Das, A.T. et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. *J. Virol.* 78, 2601–2605 (2004).
- Ueda, O. Respiratory syncytial virus. I. Concentration and purification of the infectious virus. *Acta. Med. Okayama* 32, 265–272 (1978).
- Durban, J.E. et al. The role of IFN in respiratory syncytial virus pathogenesis. *J. Immunol.* 168, 2444–2452 (2002).
- Reinhart, B.J., Weinstein, E.G., Rhoades, M.W., Bartel, B. & Bartel, O.P. MicroRNAs in plants. *Genes Dev.* 16, 1616–1626 (2002).

## **EXHIBIT 2**



# Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

Bao-jian Li<sup>1,2,7</sup>, Qingquan Tang<sup>3,7</sup>, Du Cheng<sup>2,7</sup>, Chuan Qin<sup>4,7</sup>, Frank Y Xie<sup>2,3</sup>, Qiang Wei<sup>4</sup>, Jun Xu<sup>3</sup>, Yijia Liu<sup>3</sup>, Bo-jian Zheng<sup>5</sup>, Martin C Woodlee<sup>3</sup>, Nanshan Zhong<sup>6</sup> & Patrick Y Lu<sup>3</sup>

Development of therapeutic agents for severe acute respiratory syndrome (SARS) viral infection using short interfering RNA (siRNA) inhibitors exemplifies a powerful new means to combat emerging infectious diseases. Potent siRNA inhibitors of SARS coronavirus (SCV) *in vitro* were further evaluated for efficacy and safety in a rhesus macaque (*Macaca mulatta*) SARS model using clinically viable delivery while comparing three dosing regimens. Observations of SARS-like symptoms, measurements of SCV RNA presence and lung histopathology and immunohistochemistry consistently showed siRNA-mediated anti-SARS efficacy by either prophylactic or therapeutic regimens. The siRNAs used provided relief from SCV infection-induced fever, diminished SCV viral levels and reduced acute diffuse alveoli damage. The 10–40 mg/kg accumulated dosages of siRNA did not show any sign of siRNA-induced toxicity. These results suggest that a clinical investigation is warranted and illustrate the prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents.

The outbreak of SARS has posed an urgent need to understand its disease pathogenesis<sup>1–3</sup> and the biology of its causative agent, now identified as SCV<sup>4–6</sup>. Individuals with SARS usually develop a high fever followed by severe clinical symptoms including acute respiratory distress syndrome with a diffuse alveolar damage (DAD) at autopsy<sup>2,4,9</sup>. The containment of SARS has been achieved largely through traditional quarantine and sanitation measures<sup>9,10</sup>. Because SARS is a newly emerging disease, a safe and effective vaccine is not yet available<sup>11</sup>, although some candidate vaccines have been advanced to monkey models and clinical testing<sup>12–15</sup>. To treat individuals with SARS, combinations of existing drugs, including ribavirin, antibiotics, anti-inflammatory steroids and immune stimulants, have achieved some clinical success<sup>16–18</sup>. Many ongoing efforts to develop SARS-specific drugs, such as screening of small-molecule inhibitors and current biologic approaches, will clarify the strengths and weaknesses of each approach, based on the ultimate success rate and the time and cost incurred<sup>19,20</sup>.

The identification of SCV as the causative pathogen of SARS was achieved mainly by demonstration that exposure of cynomolgus macaques to SCV resulted in symptoms similar to those of individuals with SARS<sup>1,2</sup>. Meanwhile, development of macaque models became important not only for understanding SARS pathogenesis but also for evaluation of potential vaccines and therapeutics<sup>11–13,16,19,20</sup>. Recently, a Rhesus macaque SARS model was established with intranasal instillation of SCV strain PUMC01, showing many elements of pathology similar to those of individuals with


SARS<sup>21,22</sup>. The pathogenesis includes elevated body temperature, low appetite and acute DAD clearly visible at 7 d after infection (d.p.i.), but with somewhat worse severity than other macaque SARS models<sup>19,20</sup>, offering an ideal model for evaluation of therapeutic candidates.

The search for developing antiviral agents directly from viral genome sequences has led to short interfering RNA (siRNA), the mediator of a sequence-selective inhibition known as RNA interference (RNAi)<sup>23</sup>. We reported a screen of 48 siRNA candidates targeting elements throughout the entire SCV genome and identified several siRNAs active in SCV-infected fetal Rhesus monkey kidney (FRhK-4) cells<sup>24</sup>, distinct from other active siRNA reported by other labs<sup>25–28</sup>. However, translation of *in vitro* siRNA activity into clinically useful therapeutics depends on a clinically acceptable means for administration. Therefore, siRNAs showing prominent prophylactic and therapeutic activity in cell culture<sup>24</sup>, referred to as siSC2 and siSC5, were further evaluated *in vivo*, first using a reporter gene assay in mice and subsequently using a clinically acceptable intranasal administration in the recently established Rhesus macaque SARS model<sup>21,22</sup>. The study provided strong evidence that these siRNA agents are potent both for prophylactic and therapeutic treatment of SARS infection, and they lack toxicity in this nonhuman primate model. The results support the growing expectation that siRNA can fulfill the need for moving rapidly from gene sequence to targeted therapeutic agents for many previously intractable disease targets.

<sup>1</sup>Biotechnology Research Center of Sun Yat-sen University, and Key Laboratory of Gene Engineering of Ministry of Education of the State, Guangzhou, China.

<sup>2</sup>Guangzhou Top Genomics, Ltd., Guangzhou, China. <sup>3</sup>Intradigm Corporation, 12115 K Parklawn Drive, Rockville, Maryland 20852, USA. <sup>4</sup>Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. <sup>5</sup>Department of Pathology, University of Hong Kong, Hong Kong, China. <sup>6</sup>Guangzhou Institute of Respiratory Diseases, Guangzhou, China. <sup>7</sup>These authors contributed equally to this work. Correspondence should be addressed to P.Y.L. (patricklu@intradigm.com) or N.Z. (nanshan@vip.163.com).

Published online 21 August 2005; doi:10.1038/nm1280



## RESULTS

### Selection of potent anti-SCV siRNAs

Two siRNA duplexes, siSC2 and siSC5, targeting the SCV genome at Spike protein-coding and ORF1b (NSP12) regions (Fig. 1a), respectively, were chosen for *in vivo* studies for the following reasons: (i) their targeted sequences show a 100% homology to strain TOR-2 used in the cell-culture study<sup>24</sup>, to strain PUM001 used in the macaque model<sup>21,22</sup> and to another 100 published SCV strains isolated during different phases of SCV evolution as recently defined<sup>26</sup> with wide geographic distributions around the world; (ii) they are the two most potent inhibitors for reducing SCV replication in FRhK-4 cells among a set of active siRNA duplexes selected from 48 siRNA duplexes targeting the entire SCV genome<sup>23,24</sup>; (iii) a synergistic anti-SCV activity was observed when a combination of siSC2 and siSC5 was applied in the cell-culture study showing the strongest prophylactic and therapeutic effects (Fig. 1b,c)<sup>24</sup>; (iv) their targeted sequences share no homology with the human genome, avoiding potential nonspecific knockdown of the endogenous genes of an individual receiving this type of treatment. In addition, two unrelated siRNA duplexes, siCONa and siCONb, with no homology to either the human genome or the SARS genome, validated in the cell-culture study<sup>24</sup>, show no RNAi activity for SCV inhibition, and were chosen as the negative control (Supplementary Fig. 1 online).

### siSC2 and siSC5 duplexes were active in mouse lung

To insure *in vivo* activity of the siSC2-siSC5 combination (siSC2-5) with a clinically viable delivery method we first established a luciferase-based reporter gene system, containing both siSC2 and siSC5 targeted sequences between a cytomegalovirus promoter and the luciferase coding region. Cotransfection of pCI-scLuc and siSC2-5 into cultured cells confirmed that siSC2-5 can specifically knock down luciferase expression (data not shown). To identify a clinically viable carrier for siRNA delivery into mouse lung, we selected two carriers currently in clinical use, D5W solution<sup>23</sup> and Infusurf solution<sup>30</sup>, which have been applied in delivery of DNA<sup>31</sup> and siRNA<sup>32</sup> to animal models. Twenty-four hours after intratracheal administration of 30 µg of pCI-scLuc plasmid DNA and siSC2-5 in 100 µl of D5W or Infusurf solution into BALB/c mouse lungs, we analyzed luciferase expression in the lung tissues. Co-delivery of pCI-scLuc plasmid with siSC2-5 in D5W solution resulted in a higher level of reporter gene

**Figure 1** Selection and validation of siRNA duplexes targeting SCV sequence. (a) The RT-PCR-amplified region is marked at the most upstream region of open reading frame 1 (ORF1). The siSC2- and siSC5-targeted regions (red dashed) were also marked within the Spike- and NSP12-coding regions of the SCV genome, respectively. Black arrows indicate the locations of the two targeted sequences within the viral RNA genome and gray arrowheads indicate mutation sites. Electron microscopy images of SCV particles are indicated by arrows within SCV-infected FRhK-4 cell (b) and the SCV-infected FRhK-4 cell treated with siSC2-5 (c). Scale bar in b and c, 200 nm. (d) Luciferase expression (measured in relative luciferase units, RLU) in mouse lungs after co-delivery of the expression plasmid pCI-sCLuc and either siSC2-5 or siCONC-d, in either D5W or Infasurf solution. Scale bar in d, 200 nm. \* $P < 0.05$ ,  $n = 5$ .

expression and a stronger RNAi effect than that delivered in the Infusair solution (Fig. 1d). We noted that TransIT-TKO and polyethyleneimine have been reported as carriers for intranasal<sup>33</sup>, intratracheal<sup>34</sup> and intravenous<sup>35</sup> deliveries of siRNA into mouse models for treatment of influenza virus and respiratory syncytial virus infections. But those carriers are not feasible for clinical use, especially polyethyleneimine, because it can induce severe lung inflammation through either intravenous or intratracheal delivery in mice based on our experience (data not shown) and literature reports<sup>36,37</sup>. The substantial silencing effect achieved in mouse lungs strongly supported that siSC2-5 is a potent inhibitor of SCV RNA, but also that D5W is a very effective carrier for siRNA in the mammalian respiratory tract. In addition, a lack of visible lung damage after intratracheal delivery of 30 µg siRNA and 30 µg plasmid DNA together provided a safe baseline for siRNA dosing to the respiratory tract of larger mammals.

### SCV-induced SARS-like symptoms in monkey

We used a total of 21 macaques in this study, including five groups ( $n = 4$ ) infected with SCV and one individual without SCV infection. The five groups consisted of two control groups—viral infection control and non-specific siRNA control—and three treatment regimen groups—prophylactic treatment, co-delivery treatment and postexposure treatment. After anesthetizing the macaques, we infected them with SCV at a dosage of 105 times the half-maximal tissue culture infectious dose (TCID<sub>50</sub>) in 1 ml PBS solution through intranasal instillation. We also administered the siSC2-5 or the combination of siCONa and siCONb (siCONa+b) through the same route at 30 mg per dose in 3 ml DSW solution, with different dosing regimens (Table 1).

Initial observations indicated that all SCV-infected macaques developed SARS-like symptoms, but those in the control groups showed a greater severity than that reported in the cynomolgus macaque SARS model<sup>19</sup>. For example, all macaques in the viral infection control group and the nonspecific siRNA control group developed an elevated body temperature, in some cases lasting for the entire 20-d study period. In contrast, 10 of 12 macaques from the siSC2–5-treated groups showed a milder elevation of body temperature. All animals displayed a loss of appetite and some became agitated and aggressive. General observation of the lung histology specimens indicated that lung lesions developed with congestion and palpable

Table 1 Study design and dosing regimen

Groups	Viral infection control	Non-specific sequence control	Prophylactic treatment	Co-delivery treatment	Postexposure treatment
Cohort (n = 4)	007, 205, 206, 212	163, 167, 202, 208	130, 138, 151, 203	002, 021, 077, 166	210, 015, 214, 023
Sex	M, M, F, F	M, M, F, F	F, F, M, M	F, M, M, F	F, M, M, F
Age (years)	3	3	3	3	3
Body weight	3.4 ± 0.2	3.6 ± 0.2	3.4 ± 0.2	3.7 ± 0.3	3.1 ± 0.5
Viral dosage (1 ml)	10 <sup>5</sup> TCID <sub>50</sub>	10 <sup>5</sup> TCID <sub>50</sub>	10 <sup>5</sup> TCID <sub>50</sub>	10 <sup>5</sup> TCID <sub>50</sub>	10 <sup>5</sup> TCID <sub>50</sub>
siSC2-5			30 mg/3 ml/dose	30 mg/3 ml/dose	30 mg/3 ml/dose
siCONa-b		30 mg/3 ml/dose			
Dosing regimen	-4 h Co-delivery 4 h 24 h 72 h 120 h	✓ ✓ ✓ ✓ ✓	✓	✓ ✓ ✓ ✓	✓ ✓ ✓ ✓
Total dosage		120 mg/120 h	30 mg/120 h	120 mg/120 h	90 mg/120 h
Termination at Day 7:	205, 206	167, 202	138, 151	002, 077, 166	015, 210
Termination at Day 20:	007, 212	163, 208	130, 203	021	023, 214

We used 20 Rhesus monkeys belonging to five test groups in the study with the same viral titer challenge but different drug dosing regimens of siRNA. We tested four monkeys in each group and necropsied at either 7 or 20 d.p.i. in a biohazard level 3 environment. We used one additional monkey, #921, as a "no viral infection" control and collected lung tissue for histology analysis. Cohort indicates groups of monkeys and numbers indicate macaque identification numbers. Termination indicates that observations were terminated because animals were killed.

modules, which were scattered in distribution and were localized particularly at the posterior part of different lobes<sup>22</sup>. The most severe lung damage occurred focally and was surrounded by large areas of obvious pathology, whereas milder lung damage appeared with smaller areas of pathology.

To better characterize the pathological changes, we adopted a six-grade scoring system to describe the severity of the lung damage from least severe to most severe: (i) "–", (ii) "±", (iii) "+", (iv) "++", (v) "+++", and (vi) "++++" (Fig. 2a–f). Liver enzymatic analysis showed an evident increase of alanine aminotransferase, lactic acid dehydrogenase, creatine kinase and aspartate aminotransferase after SCV infection of all 20 macaques from every tested group, at 7 d.p.i. Notably, routine blood examination indicated a marked increase of hemoglobin and platelets in all SCV-infected macaques, which is contradictory to other reports on the SARS macaque model<sup>20</sup> and on SARS-infected individuals<sup>9,10,15</sup> (Supplementary Tables 1 and 2 online). The mechanism underlying the differences in behavior of these primate SARS models requires further investigation.


#### SCV infection caused acute DAD in monkey lungs

SCV-induced DAD in the lower airway usually is observed in individuals with SARS who have had the disease for more than 10 d<sup>9</sup>, whereas the SCV-infected macaque lungs started developing acute DAD at 4 d.p.i.<sup>19,22</sup>. In histopathological and immunohistochemical (IHC) inspections, we found that most of the lungs, at both 7 and 20 d.p.i., displayed acute DAD with various degrees of severity. The typical features of SCV infection-induced lung damage include broken alveolar walls and interstitial edema (Fig. 3a), hyaline membrane formation along the alveoli and pneumocyte desquamation (Fig. 3b), damaged alveolus filled with hemorrhage and pneumocytes with nuclear enlargement, prominent nucleolus and amphophilic granular cytoplasm (Fig. 3c), and interstitial infiltrates with neutrophils, lymphocytes and macrophages (Fig. 3d). Within damaged lung tissues, we identified viral-infected pneumocytes, infiltrated neutrophils, lymphocytes and monocytes using IHC stains of keratin (Fig. 3e), CD68 (Fig. 3f), CD4, CD8 and CD35 (data not shown). These characteristics were very similar to those observed in individuals

with SARS<sup>9,10</sup> and SARS macaque models<sup>19–22</sup>. Therefore, this Rhesus macaque model provides an ideal system for evaluation of new therapeutic agents against SARS.

#### siRNA suppressed SARS-like symptoms


The body temperature of the infected macaque is a key indicator not only for the severity of SARS-like symptoms but also for effectiveness of the treatment. We recorded body temperature of every animal daily until it was killed. Comparison of the mean body temperatures of all



**Figure 2** Severity of lung histopathology in SCV-challenged macaques. All lung histology sections were stained with H&E (original magnification, ×100). (a) Normal lung section from macaque #921 without SCV infection "–". (b) Minor inflammation "±", from macaque #138, slight broadening of alveolar septa and sparse monocyte infiltration. (c) Apparent inflammation "±", from macaque #077, hemorrhage in septa, elastic fibers of alveolar wall distorted as shown by silver staining. (d) Early symptom of acute DAD "±", from macaque #015, alveolus septa broadening with increasing infiltration of inflammatory cells. (e) Typical symptom of acute DAD "++", from macaque #212, extensive exudation and septa broadening, shrinking of alveoli caused by pressure, restricted fusion of the thick septa, obvious septa hemorrhage, ruptured elastic fiber of alveolar wall and slight cell infiltration in alveolar cavities. (f) Severe acute DAD "++++", from macaque #202, massive cell infiltration and alveoli shrinking, sheets of septa fusion, necrotic lesions at the hemorrhagic septa and massive cell infiltration in alveolar cavities.

**Figure 3** Histopathological characteristics of SCV-infected macaque lungs. (a,b) Lung sections were stained with H&E (original magnification,  $\times 100$ ). (a) Section from macaque #214 shows the alveolar walls collapsed and acute diffuse interstitial injury with interstitial edema (arrows) at an early stage of the disease. (b) Section from macaque #015 shows hyaline membrane formation (arrows) along the alveoli and pneumocyte desquamation. (c,d) Lung sections stained with H&E (original magnification,  $\times 200$ ). (c) Section from macaque #166 shows that damaged alveoli were filled with hemorrhage and inflammatory cells (upper arrows) and pneumocytes with nuclear enlargement, prominent nucleolus and amphophilic granular cytoplasm resulting in focal giant-cell formation (lower arrows). (d) Section from macaque #202 shows inflammatory cells, including neutrophils, lymphocytes, macrophages and monocytes, were present in the damaged alveoli. (e) IHC staining of SCV-infected monkey lung section with keratin-specific monoclonal antibody indicates the epithelial origin of the pneumocytes (arrows) (original magnification,  $\times 200$ ). (f) IHC staining of SCV-infected monkey lung section with CD68 monoclonal antibody indicates microphage infiltrates (arrows) (original magnification,  $\times 500$ ).


five groups (Fig. 4a) revealed significantly lower temperatures of all treated groups (prophylactic, co-delivery and postexposure treatment groups; below  $38.9^{\circ}\text{C}$ ) versus the control groups (viral infection and nonspecific siRNA groups), which had temperatures above  $39.1^{\circ}\text{C}$ , indicating a fever status<sup>22</sup>. The prophylactic treatment group had the lowest temperature ( $38.7^{\circ}\text{C}$ ), close to the normal body temperature of Rhesus monkey ( $38.5^{\circ}\text{C}$ ). Examining the distribution of the average body temperature at each time point throughout the entire 20-d period with trend regression (Fig. 4b), we found that viral infection and nonspecific siRNA control groups had consistently elevated temperatures above  $39^{\circ}\text{C}$ . Macaque #212 from the viral infection control group had a high fever ( $40^{\circ}\text{C}$ ) at 4 d.p.i. and the fever lasted until the macaque was killed at 20 d.p.i. for pathology analysis, at which time it showed a severe lung damage that we scored as “+++”. A similar situation was seen for macaque #208 of the nonspecific siRNA group. The comparison of mean body temperature trend regression clearly shows the prophylactic and therapeutic effects of siSC2-5 on suppression of fever induced by SCV infection. In addition, the inhibitory effects of siSC2-5 also resulted in lowering



SCV-specific IgG titer in blood samples (Fig. 4c). We detected SCV-specific IgG levels in viral control and nonspecific siRNA control groups as early as 10 d.p.i., but not in the co-delivery and postexposure treatment groups. We were able to detect SCV-specific IgG titers of all groups at 19 d.p.i.

#### siRNA protected lung from severe acute DAD

In the viral infection control group, macaques #212 and #206 had severe acute DAD with pathological changes in a large portion of the lungs, including interstitial infiltrates and lung damage that we scored as “+++”. Macaque #202 of the nonspecific siRNA control group showed even more severe acute DAD in a large portion of the lung, with massive cell infiltration and alveoli shrinkage, sheets of septa fusion, necrotic lesions at the hemorrhagic septa and extensive loss of alveolar and bronchiolar epithelium, representing a typical lung damage score of “++++”, the worst case among all 20 SCV-exposed macaques. All macaques from both viral infection and nonspecific siRNA control groups suffered from severe acute DAD with a lung damage score of “+++”. On the other hand, lung tissues from all three siSC2-5-treated groups (prophylactic, co-delivery and postexposure treatment groups) showed relatively mild severity of acute DAD and none showed lung damage beyond a score of “++”. The comparison of lung histopathological scores of all groups



**Figure 4** siSC2-5 relieved SARS symptoms. (a) Comparison of mean body temperature. Mean body temperature represents mean value of average body temperature of each group during the 20-d period. \*\* $P < 0.01$  for *t*-test compared to viral infection control group,  $n = 20$ . IC, viral infection control; NS, nonspecific siRNA control; PL, prophylactic treatment; CD, co-delivery treatment; PE, postexposure treatment. (b) Distribution of the average body temperatures throughout the 20-d period. The regression analysis was conducted based on the average body temperature of each group on each day. The average body temperature of each group was calculated with  $n = 4$  before 7 d.p.i. and  $n = 2$  afterward. (c) IgG titers of SCV-specific antibody in serum samples were measured at 10 d.p.i. (left) and 19 d.p.i. (right). (d) The average histopathological scores of each group, including lung samples collected at both 7 d.p.i. and 20 d.p.i., were compared against the viral infection control group. \* $P < 0.05$ ,  $n = 4$ .

indicates that the siSC2-5-treated macaques were protected from severe acute DAD (Fig. 4d).

### siRNAs inhibited SCV replication in monkey respiratory tract


We analyzed oropharyngeal swab samples at 4 d.p.i. with quantitative real-time PCR (Q-RT-PCR). They showed that SCV viral RNA was detectable in all samples from the viral infection and nonspecific siRNA control groups, but undetectable in 75% of the samples from the siSC2-5 treatment groups (Fig. 5a). This result indicated the possible inhibition of SCV infection and replication through siSC2-5-facilitated viral RNA degradation in upper airway epithelial cells. The three positive samples from the treatment groups suggest that the dosing regimens were unable to totally eliminate SCV infection. The histopathology analyses of those macaques (#130, 166 and 210) have indeed shown some degrees of lung damage at scores of "+" or "++". The Q-RT-PCR detection of the randomly selected lung tissue specimens also showed the presence of the SCV RNA (Supplementary Fig. 2 online). We also applied the oropharyngeal swab samples for active viral rescue in the Vero cell culture, showing that samples from all five groups were positive for live SCV particles. To evaluate SCV infection in deeper lung, we carefully inspected IHC staining images from each lung section, with SCV antigen-specific monoclonal antibody. The samples from viral infection and nonspecific siRNA groups presented much more infected cells (Fig. 5b–d) than those from siSC2-5-treated groups (Fig. 5e–g). The SCV-infected cells include the type I pneumocytes (Fig. 5c,e), type II pneumocytes (Fig. 5f) and macrophages (Fig. 5d), the presence of which was consistent with the observation in the previous studies with macaque models and in individuals with SARS<sup>9,10,19–22</sup>. We further counted the infected cells in each lung section and compared these numbers for the five groups. The lungs from all three siSC2-5 treatment groups had significantly lower counts of the SCV-infected cells (Fig. 5h), which indicated that the siRNA treatments were able to inhibit SCV replication and spread within the monkey lungs.

### siRNA was safe for prophylactic and therapeutic treatments

Evaluation of a new biological agent such as siRNA for its therapeutic utility depends not only on its efficacy in treating diseases, but also on its tolerability and safety. Our study put both efficacy and safety in equal consideration in order to define a therapeutic window for use of siRNA as an anti-SARS agent through airway administration. The choice of the siSC2-5 dosage at 10 mg/kg was based on the mouse study described above and study reports on antisense oligomers<sup>38</sup>. Through observation of behavior patterns of Rhesus macaques during the entire study and examination of the organs of killed animals with various siRNA dosing regimens, no safety concerns arose. The treatment groups lacked evidence of inflammation or toxicity not attributable to the SCV infection. The total accumulated dosage of siRNA administered to individual macaques ranged from 10 mg/kg to 40 mg/kg and did not cause any visible differences in appearance, behavior or sign of organ damage when examined by autopsy and necropsy. In addition, we found no statistically significant differences in internal organ coefficients among the five groups (Supplementary Table 3 online). Reports of potential "off-target" effects of the siRNA agent<sup>39–41</sup> have been mostly based on cell-culture experiments, without evidence for *in vivo* siRNA toxicity<sup>39,41</sup>. From the results of routine blood examination and liver enzymatic analysis, we found some increases of alanine aminotransferase, lactic acid dehydrogenase, creatine kinase, aspartate dehydrogenase, hemoglobin and platelet levels in the blood samples. Because those increases are from SCV-infected macaques, with or without siRNA treatment, they were probably results from the viral infection rather than the siRNA treatments (Supplementary Tables 1 and 2 online).

### DISCUSSION

Although concern remains over whether the macaque SARS models are clinically relevant<sup>14,20–22</sup>, the Rhesus macaque model used here, which used the high-virulence SCV strain PUMC01 (ref. 6), mirrors the sequence of pathogenesis in humans with SARS<sup>9,10</sup>.



**Figure 5** siSC2-5 inhibits SCV replication. (a) Q-RT-PCR detection of SCV RNA (both genomic and RNA from open reading frame 1) from oropharyngeal swab specimens collected at 4 d.p.i. IC, viral infection control; NS, nonspecific siRNA control; PL, prophylactic treatment; CD, co-delivery treatment; PE, postexposure treatment. Numbers on x-axis refer to animal identification number. (b–g) The SCV-specific antigen was detected in alveoli of the deep lungs including various cell types (original magnification,  $\times 200$ ), confirmed by the specific staining with monoclonal antibodies. (b) The upper arrow indicates an SCV-infected type II pneumocyte and the lower arrow indicates an infected alveolar macrophage. (c) Arrows indicate SCV-infected epithelium-originated type I pneumocytes. (d) Arrows indicate SCV antigen-positive alveolar macrophages. (e–g) Arrows indicate SCV-infected cells scattered within the siSC2-5-treated lungs. (h) Comparison of average SCV-infected cell counts of each group with that of viral infection control group. IC, viral infection control; NS, nonspecific siRNA control; PL, prophylactic treatment; CD, co-delivery treatment; PE, postexposure treatment. \* $P < 0.05$ ,  $n = 4$ .

and the cynomolgus macaque SARS model<sup>14,19</sup>. Clear clinical relevance of this model can be found in most of the parameters studied, including elevated body temperature, lung pathology and SCV antigen detection in epithelial-originated type I pneumocytes, type II pneumocytes and macrophages, providing strong support that the model has the attributes required for evaluation of siRNA candidate therapeutic agents.

Here we administered siSC2-5 by the same intranasal route as the SCV challenge, with prophylactic, concurrent or early postexposure treatments within a period of 5 d.p.i. All three different treatment regimens achieved potent suppression of SCV-induced SARS pathogenesis. Detection of SCV RNA genome with RT-PCR showed that only 25% of oropharyngeal swab samples from the treated group were positive versus all samples from the control groups. Similarly, using IHC detection, SCV-infected cell counts were significantly decreased in the lung sections from the treated groups. Along with the reduced viral load was a substantial reduction in SARS-like symptoms and lung histopathology, including significantly lowered mean body temperatures in all siSC2-5-treated groups, and no lung damage beyond a score of "++". In contrast, the mean body temperatures in the control groups indicated a fever status, along with substantial lung damage of "+++" or "++++".

We designed this study to investigate siRNA-mediated anti-SCV effects in both the upper airway and deep lung of SCV-exposed macaques that occurred during an early phase of viral infection and disease progression. The impact of siSC2-5 on the early phase of SCV infection was first shown in the mucosal epithelial cells of the upper respiratory tract, as expected because both the siSC2-5 and SCV were administered through intranasal instillation and all siRNA dosing was complete within the first 5 d. This anti-SARS efficacy of siSC2-5 could be the result of one or more of the following three mechanisms: protection of cells from SCV infection, degradation of SCV mRNA inhibiting viral protein synthesis in infected cells<sup>24</sup>, or obstruction of SCV genome replication and spread to uninfected cells. Considering that SARS-specific neutralizing antibody in SCV-infected macaques can be detected as early as 10 d.p.i., we speculated that the clinical benefit of siRNA-mediated anti-SARS activity observed in this study was the consequence of combined activities of the siRNA agent and the neutralizing antibody, suggesting that multiple antiviral mechanisms were operative.

Delivering siSC2-5 before SCV infection in the prophylactic treatment group using a single dose was able to achieve a comparable inhibitory effect to that of the co-delivery and postexposure treatment groups. The prophylactic anti-SCV activity resulted in a lower body temperature, milder lung damage, less viral RNA detected and lower numbers of SCV-infected cells in the lung, in comparison with co-delivery and postexposure treatment groups. The mechanism of action might be the result of direct degradation of viral RNA by preexisting siSC2-5 within the upper airway cells upon entry of the viral particle, blocking replication and spread of SCV particles. In addition, a cellular antiviral activity induced by siRNA transfection other than an interferon response may also have a role<sup>24</sup>.

The interferon response to siRNA duplexes as in cell-culture studies has raised concerns about the specificity of RNAi in animals<sup>42-45</sup>. But a recent *in vivo* study using siRNA against RSV in mouse lung showed a lack of detectable siRNA-induced interferon<sup>29</sup>. This observation was also echoed by a report that intravenous siRNA delivery in mice resulted in a lack of interferon induction *in vivo*<sup>46</sup>. The siSC2-5 and siCONa-b we used in the study contain neither the 5'-UGUGU-3' nor the 5'-GUUCCUCAA-3' motifs suspected to be immunostimulatory elements when in association with transfection reagents<sup>44,45</sup>. We did

not find anti-SCV activity when using the control siCONa-b. Therefore, we conclude the anti-SARS activity is probably the result of siSC2-5-mediated SCV RNA degradation within cells throughout the pulmonary tracts of the treated macaques.

Release of proinflammatory cytokines from alveolar macrophages has been proposed to have a prominent role in SARS pathogenesis and to be a point for intervention<sup>9</sup>. The presence of hemophagocytosis<sup>47,48</sup> or an interferon- $\gamma$ -related cytokine storm in individuals with SARS<sup>49</sup> complicates our understanding of SARS pathogenesis but also argues against use of interferon therapy in clinical treatment, despite studies in cell culture<sup>18</sup>, a macaque model<sup>19</sup> and individuals with SARS<sup>50</sup> that showed inhibition of SCV with interferon treatment. In contrast to such proinflammatory cytokine treatments, intranasal delivery of siRNA offers a unique method for high-specificity inhibition of SCV with minimal induction of a proinflammatory cytokine antiviral response that may help to avoid exacerbation of symptoms and lung damage. Here, we present evidence for a strong anti-SARS activity without any visible adverse effects through intranasal administration of siSC2-5 in a clinically viable aqueous solution with a nonhuman primate SARS model. Our data suggest that clinical testing of siSC2-5 agent as a SARS treatment is warranted. This work also shows the tremendous potential for siRNA to enable rapid development of treatments for emerging infectious agents, and for powerful 'targeted' therapeutics acting at the level of gene expression.

## METHODS

**SCV and Rhesus macaque model.** The SCV strain PUMC-01 was isolated from an individual in the Peking Union Medical Hospital and propagated in cultured Vero cells. The Rhesus macaque (*Macaca mulatta*) SARS model was developed using intranasal inoculation of PUMC01 SCV<sup>14,29</sup>. We performed our studies in Biosafety Level 3 laboratories exclusively assigned for SCV research at the Institute of Laboratory Animal Science of Chinese Academy of Medical Sciences, after approval of our animal study protocol by the Institutional Animal Welfare Committee. We inoculated monkeys with PUMC01 ( $10^6$  TCID<sub>50</sub>/1.0 ml) through intranasal instillation, mimicking the natural route of SCV infection of humans with SARS. We also delivered 30  $\mu$ g of siSC2-5 and siCONa-b in 3 ml of D5W solution with intranasal instillation. We confirmed that all monkeys were negative for the presence of SCV-specific antibody before SCV challenge.

After the SCV challenge and siRNA dosing, we observed the clinical signs of the macaques daily, including body temperature, size of lymph nodes, body weight, coughing, sneezing, appetite, aggressiveness, etc. At 4 d.p.i., we took oropharyngeal swabs from SCV-challenged monkeys for detection of viral RNA using RT-PCR and viral re-isolation. We collected blood samples on 4, 7, 10 and 19 d.p.i. for routine laboratory examination, including liver enzymatic analysis and the detection of SCV-specific antibody. The ELISA Diagnosis kits for detection of SCV-specific IgG or IgM (Hau Da Biotech) were used according to the manufacturer's protocol.

We collected lungs after necropsy of the macaques at 7 and 20 d.p.i. for histopathological analyses. We also collected other organs for inspection of morphology and appearance, followed by comparison of the internal organ coefficients of each group, based on wet weight of organ per 100 g of average body weight (Supplementary Table 3 online).

**siRNA duplexes.** We selected two SCV-specific siRNA duplexes, siSC2 and siSC5, based on a previous *in vitro* study<sup>24</sup> and used them as a mixture (siSC2-5) consisting of an equal amount of each siRNA duplex. We also used a pair of control siRNA duplexes, siCONa and siCONb, as a mixture (siCONa-b). We used another pair of unrelated control siRNA duplexes, siCONc and siCONd, as a mixture in the mouse study (siCONc-d). All siRNA duplexes consisted of two complementary 21-nucleotide RNA strand with 3' dTdT overhangs, and were chemically synthesized (Qiagen). The siRNA sequences were as follows: siSC2: (forward) 5'-GCUCCUAAUUAUACUCAAACGdtdt-3', (reverse) 3'-dtdtCGAGGAGUUAUUGAGUGAGUG-5'; siSC5: (forward) 5'-GGAUGAGG AAGGCAUUAU dtdt-3', (reverse) 3'-dtdtCCUACUCCUCCUGUUAUUAU-5'.

siCONa: (forward) 5'-CGGCGGAGAGCAACUGCAAdttd-3', (reverse) 3'-ddt GGGGCGGCGGAGAGCAACUGCAAdttd-3'; siCONb: (forward) 5'-GCUAGGAAACGA UAGGCGGCGGAGAGCAACUGCAAdttd-3', (reverse) 3'-ddt GCUAGGAAACGA UAGGCGGCGGAGAGCAACUGCAAdttd-3'; siCONc: (forward) 5'-GCGAGCGGAGAGCAACUGCAAdttd-3', (reverse) 3'-ddt GCGAGCGGAGAGCAACUGCAAdttd-3'; siCONd: (forward) 5'-GCGAGCGGAGAGCAACUGCAAdttd-3', (reverse) 3'-ddt GCGAGCGGAGAGCAACUGCAAdttd-3'.

**Electron microscopy.** We harvested FRhK-4 cells infected by SCV, with or without siSC2-5 treatment, and fixed them in epoxy resin (Polysciences). We examined ultrathin sections (70 nm thick) under a Philips EM2085 electron microscope at 80 kV as described previously<sup>24</sup>.

**Delivery of nucleic acid into mouse lungs.** We divided 20 6–8-week-old BALB/c mice into four groups ( $n = 5$ ). We tested two carrier solutions, RNase-free DSW (5% o-glucose in water, wt/vol, made in-house) and Infusur solution (ONY Inc.), for delivering siSC2-5, siCONc-d and pCI-scLuc plasmid. We mixed 30 µg of pCI-scLuc and 30 µg of corresponding siRNAs in 100 µl carrier solutions and intratracheally administered them into the mouse lungs. We constructed the pCI-scLuc plasmid by inserting a DNA fragment containing siSC2-5 and siSC5-targeted sequence DNA between its cytomegalovirus promoter-driven transcriptional initiation site and luciferase-coding sequence. At 24 h after delivery, mice were killed and lung tissues were harvested and homogenized in 800 µl of 1× Reporter Lysis buffer (Promega) using Lysing Matrix D (Bio 101 System) in a FastPrep-FP120 (Bio 101 System) at speed 4.0 for 40 s. After centrifugation at 12,000 r.p.m. for 2 min at 4 °C, we used 10 µl of supernatant for measurement of luciferase activity using a Luciferase Assay kit (Promega) and a luminometer (Analytical Luminescence Laboratory) following the manufacturer's protocol. We performed the animal experiment under a protocol approved by the Institutional Animal Care and Use Committee of the Biomedical Research Institute.

**Q-RT-PCR and SCV re-isolation.** We isolated total cellular RNA using a QIAamp RNA isolation kit (Qiagen). We synthesized the first strand cDNA using RNase H<sup>-</sup> reverse transcriptase and random primers (Invitrogen), according to the manufacturer's protocol. The forward and reverse primers, targeting upstream of open reading frame 1 (ORF1), and the fluorescent probe used for PCR are: 5'-GCATGAAATGCTGGTTCAC-3' (ORF1 forward), 5'-GCATTCCT CTTTGAAGATGTC-3' (ORF1 reverse) and FAMAGCTACGAC CACGAGACACCCCTTGGAAATRMA (fluorescent probe for PCR). We performed RT-PCR using ABI7900 Sequence Detection System (ABI). All PCR experiments were done in triplicate<sup>25</sup>. We conducted SCV re-isolation using the swab samples by serial passage on Vero cell culture as previously described<sup>21,22</sup>.

**Lung histopathology and IHC analyses.** We obtained lung tissue blocks from the right upper and right middle lobes and performed pathology analysis as described previously<sup>22</sup>. We determined the severity of lung damage based on observations of five different sections of each lung by readouts from three independent pathologists who were blinded to experimental conditions. To quantify pathological changes in lung after the treatment, we calculated the average histopathological scores of each group using the scoring system described above. We de-waxed wax-embedded tissue sections and rehydrated them for the IHC analysis as described previously<sup>22</sup>. We identified the cell types based on the separate staining with corresponding monoclonal antibodies using methods described previously<sup>21,22</sup>. We used viral antigen detection with IHC to indicate infected cells. We collected the SCV-infected cell counts within each microscopic image from every lung tissue section independently by three readouts with investigators blinded to the experimental conditions. We compared average cell counts of four lungs from each group ( $n = 4$ ).

**Statistical analysis.** We analyzed data using the Student *t*-test for luciferase expression in mouse lungs, mean body temperature, histopathology score comparison and SCV-infected cell counts. We considered results statistically significant only when  $P < 0.05$ . We conducted the regression analysis based on the average body temperature of each group at each day point. We conducted the multifactor ANOVA for the internal organ coefficient.

**Accession codes.** GenBank: SCV strain PUMC01, AY350750; strain TOR-2, AY274119; SCV complete genome sequence, NC-004718.

**Note.** Supplementary information is available on the Nature Medicine website.

# ACKNOWLEDGMENTS

This study was supported in part by the Science and Technology Commission, Guangdong Provincial Government, Guangzhou Science and Technology Bureau, Guangzhou Economic & Technological Development District, and China World Trade Corporation (Guangzhou), Top Biotech, Ltd. (Hong Kong), China. We thank C. Lu, X.S. Zhang and D.C. Zheng of Top Genomics, Ltd. (Guangzhou) for their administrative work to coordinate and facilitate the study; H. Gao, X.M. Tu, L.L. Bao, W. Deng and B.L. Zhang of Institute of Laboratory Animal Science and L. Ruan of Institute of Virology, Chinese Academy of Medical Sciences & Peking University Medical College, Beijing, for their supports during the study; W. Tian and E. Lader of Qiagen for their collaborative efforts; Y.Y. Gu of Guangzhou Institute of Respiratory Diseases for her advice on lung pathological analysis; and ONY Inc. Amherst, New York, USA for providing Infusur.

# COMPETING INTERESTS STATEMENT

The authors declare competing financial interests (see the Nature Medicine website for details).

Received 18 November 2004; accepted 10 July 2005

Published online at <http://www.nature.com/naturemedicine/>

1. Fouchier, R.A. et al. Aetiology: Koch's postulates fulfilled for SARS virus. *Nature* **423**, 240 (2003).
2. Kulkarni, T. et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *Nature* **423**, 263–270 (2003).
3. Ksiazek, T.G. et al. A novel coronavirus associated with severe acute respiratory syndrome. *N. Engl. J. Med.* **348**, 1953–1966 (2003).
4. Peiris, J.S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet* **361**, 1319–1325 (2003).
5. Guan, Y. et al. Origin and characterization of viruses related to the SARS coronavirus from animals in southern China. *Science* **302**, 276–278 (2003).
6. Chinese SARS Molecular Epidemiology Consortium. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. *Science* **303**, 1666–1669 (2004).
7. Snijder, E.J. et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. *J. Mol. Biol.* **331**, 991–1004 (2003).
8. Marra, M.A. et al. The genome sequence of the SARS-associated coronavirus. *Science* **300**, 1399–1404 (2003).
9. Nicholls, J.M. et al. Lung pathology of fatal severe acute respiratory syndrome. *Lancet* **361**, 1773–1778 (2003).
10. Peiris, J.S. et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* **361**, 1767–1772 (2003).
11. Bishit, H. et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. *Proc. Natl. Acad. Sci. USA* **101**, 6641–6646 (2004).
12. Buterov, A. et al. Mucosal immunization of African green monkeys (*Cercopithecus aethiops*) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. *Lancet* **363**, 2122–2127 (2004).
13. Yang, Z. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* **428**, 561–564 (2004).
14. Hagan, R. et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. *J. Virol.* **78**, 11416–11421 (2004).
15. Zhong, N.S. et al. Epidemiological and clinical data of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. *Lancet* **362**, 1353–1358 (2004).
16. Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. *J. Virol.* **78**, 3572–3577 (2004).
17. Hensley, L. et al. Interferon- $\beta$  and SARS coronavirus replication. *Emerg. Infect. Dis.* **10**, 317–319 (2004).
18. Sainz, B. Jr. et al. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). *Virology* **328**, 111–117 (2004).
19. Haagsmans, B.L. et al. Pegylated interferon- $\alpha$  protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nat. Med.* **10**, 290–293 (2004).
20. Rowe, T. et al. Macaque model for severe acute respiratory syndrome. *J. Virol.* **78**, 11401–11404 (2004).
21. Chen, Z. et al. Recombinant modified vaccinia virus ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. *J. Virol.* **78**, 2678–2688 (2005).
22. Qin, C. et al. An animal model of SARS produced by infection of macaca mulatta with SARS coronavirus. *J. Pathol.* **206**, 251–259 (2005).
23. Joost Hassel, P.C.J., Clapac, D. & Berkhout, B. Inhibition of virus replication by RNA interference. *J. Biol. Chem.* **279**, 607–616 (2004).
24. Zheng, B. et al. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. *Antivir. Ther.* **9**, 365–374 (2004).

25. Elmen, J. *et al.* SARS virus inhibited by siRNA. *Precinica* 2, 135–142 (2004).
26. Zhang, Y. *et al.* Silencing SARS-CoV protein expression in cultured cells by RNA interference. *FEBS Lett.* 560, 141–146 (2004).
27. Zhang, R. *et al.* Inhibiting severe acute respiratory syndrome-associated coronavirus by small interfering RNA. *Chin. Med. J. (Engl.)* 116, 1262–1264 (2003).
28. Wang, Z. *et al.* Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. *J. Virol.* 78, 7523–7527 (2004).
29. Ghanayem, N.S. *et al.* Stability of dopamine and epinephrine solutions up to 84 hours. *Pediatr. Crit. Care Med.* 2, 315–317 (2001).
30. Thomas, N.J. *et al.* Cost-effectiveness of exogenous surfactant therapy in pediatric patients with acute hypoxemic respiratory failure. *Pediatr. Crit. Care Med.* 6, 160–165 (2005).
31. Lu, P.Y., Enist, D. & Mina, M. Method of achieving persistent transgene expression. US patent application, 20030148975, FC/EP0013297 (2000).
32. Massaro, D., Massaro, G.O. & Clerch, L.B. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 287, L1066–L1070 (2004).
33. Bitko, V., Musyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. *Nat. Med.* 11, 50–55 (2004).
34. Tompkins, S.M., Lo, C.Y., Tumpsey, T.M. & Epstein, S.L. Protection against lethal influenza virus challenge by RNA interference *in vivo*. *Proc. Natl. Acad. Sci. USA* 101, 8652–8656 (2004).
35. Ge, Q. *et al.* Inhibition of influenza virus production in virus-infected mice by RNA interference. *Proc. Natl. Acad. Sci. USA* 101, 8676–8681 (2004).
36. Boeckle, S. *et al.* Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. *J. Gene Med.* 6, 1102–1111 (2004).
37. Deshpande, P. *et al.* Biodistribution study of phospholipids: a class of non-viral vectors efficient in mice lung-directed gene transfer. *J. Gene Med.* 5, 600–608 (2003).
38. Bonnard, E., Mazarguil, H. & Zajac, J.M. Peptide nucleic acids targeted to the mouse pronPPF(A) reveal an endogenous opioid tonus. *Peptides* 23, 1107–1113 (2002).
39. Semizarov, D. *et al.* Specificity of short interfering RNA determined through gene expression signatures. *Proc. Natl. Acad. Sci. USA* 100, 6347–6352 (2003).
40. Chi, J.T. *et al.* Genomewide view of gene silencing by small interfering RNAs. *Proc. Natl. Acad. Sci. USA* 100, 6364–6369 (2003).
41. Jackson, A. *et al.* Expression profiling reveals off-target gene regulation by RNAi. *Nat. Biotechnol.* 21, 635–637 (2003).
42. Sledz, C.A. *et al.* Activation of the interferon system by short-interfering RNAs. *Nat. Cell Biol.* 5, 834–839 (2003).
43. Kariko, K., Bhuyan, P., Capodici, J. & Weissman, D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signalling through toll-like receptor 3. *J. Immunol.* 172, 6545–6549 (2004).
44. Judge, A.D. *et al.* Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. *Nat. Biotechnol.* 23, 457–462 (2005).
45. Hornung, V. *et al.* Sequence-specific potent induction of IFN- $\alpha$  by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nat. Med.* 11, 263–70 (2005).
46. Heidel, J.D. *et al.* Lack of interferon response in animals to naked siRNAs. *Nat. Biotechnol.* 22, 1579–1582 (2004).
47. Ware, L.B. & Matthay, M.A. The acute respiratory distress syndrome. *N. Engl. J. Med.* 342, 1334–1349 (2000).
48. Yuen, K.Y. *et al.* Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. *Lancet* 351, 467–471 (1998).
49. Huang, K.J. *et al.* An interferon-gamma-related cytokine storm in SARS patients. *J. Med. Virol.* 75, 185–194 (2005).
50. Cinatl, J. *et al.* Treatment of SARS with human interferons. *Lancet* 362, 293–294 (2003).